These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31396700)

  • 1. A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda.
    Luo J; Nishikawa G; Prasad V
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2303-2311. PubMed ID: 31396700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved.
    Zhang SX; Fergusson D; Kimmelman J
    J Natl Cancer Inst; 2020 Sep; 112(9):886-892. PubMed ID: 32239146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical trials and licensing of monoclonal antibodies and biological medicines for cancer treatment in Brazil].
    Silva CF; Silva MV; Osorio-de-Castro CG
    Rev Panam Salud Publica; 2016 Mar; 39(3):149-156. PubMed ID: 27754528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).
    Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF
    Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal Antibodies: A Review.
    Singh S; Kumar NK; Dwiwedi P; Charan J; Kaur R; Sidhu P; Chugh VK
    Curr Clin Pharmacol; 2018; 13(2):85-99. PubMed ID: 28799485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of radio-isotopes for cancer therapy.
    Milenic DE; Brechbiel MW
    Cancer Biol Ther; 2004 Apr; 3(4):361-70. PubMed ID: 14976424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New monoclonal antibodies in renal transplantation.
    Vincenti F
    Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy.
    Cushman TR; Caetano MS; Welsh JW; Verma V
    Immunotherapy; 2018 Aug; 10(10):851-0. PubMed ID: 30073899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials.
    Reuss JE; Stern D; Foster JC; Ramaswami R; Lurain K; Chen HX; Streicher H; Kem R; Little RF; Sharon E
    JAMA Netw Open; 2020 Dec; 3(12):e2027110. PubMed ID: 33258905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Trials Associated With Drugs Approved by the Food and Drug Administration in 2015 and 2016.
    Eckert JC
    Med Care; 2020 Mar; 58(3):194-198. PubMed ID: 32106163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal Antibodies in Oncology: A Decade of Novel Options.
    Kardile V; Kulkarni A; Nadar B; Saldanha T
    Cell Biochem Biophys; 2023 Sep; 81(3):395-408. PubMed ID: 37395856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
    Bonomi PD; Gandara D; Hirsch FR; Kerr KM; Obasaju C; Paz-Ares L; Bellomo C; Bradley JD; Bunn PA; Culligan M; Jett JR; Kim ES; Langer CJ; Natale RB; Novello S; Pérol M; Ramalingam SS; Reck M; Reynolds CH; Smit EF; Socinski MA; Spigel DR; Vansteenkiste JF; Wakelee H; Thatcher N
    Ann Oncol; 2018 Aug; 29(8):1701-1709. PubMed ID: 29905778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.
    Zhu J; Zhao W; Liang D; Li G; Qiu K; Wu J; Li J
    Int J Clin Oncol; 2018 Apr; 23(2):389-399. PubMed ID: 29181651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
    Desnoyer A; Broutin S; Delahousse J; Maritaz C; Blondel L; Mir O; Chaput N; Paci A
    Eur J Cancer; 2020 Mar; 128():119-128. PubMed ID: 32037060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
    Viala M; Vinches M; Alexandre M; Mollevi C; Durigova A; Hayaoui N; Homicsko K; Cuenant A; Gongora C; Gianni L; Tosi D
    Br J Cancer; 2018 Mar; 118(5):679-697. PubMed ID: 29438365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs.
    Vokinger KN; Kesselheim AS
    Health Policy; 2019 Aug; 123(8):721-727. PubMed ID: 31229275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation.
    Omae K; Kataoka Y; Tsujimoto Y; Tsutsumi Y; Yamamoto Y; Fukuhara S; Furukawa TA
    BMC Cancer; 2019 Oct; 19(1):998. PubMed ID: 31651263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.